Options
Morphological Changes in a Severe Model of Parkinson’s Disease and Its Suitability to Test the Therapeutic Effects of Microencapsulated Neurotrophic Factors
6-OHDA
GDNF
Neuroregeneration
Parkinson’s disease
Rostro-caudal gradien...
VEGF
desipramine
dopamine
glial cell line deriv...
glial fibrillary acid...
microsphere
oxidopamine
pargyline
tyrosine 3 monooxygen...
vasculotropin
glial cell line deriv...
neuroprotective agent...
vascular endothelial ...
vasculotropin A
animal experiment
animal model
animal tissue
Article
brain nerve cell
caudate nucleus
cell count
controlled study
corpus striatum
disease severity
dopaminergic system
female
histopathology
immunoreactivity
medial forebrain bund...
microencapsulation
nigroneostriatal syst...
nonhuman
Parkinson disease
pathogenesis
protein function
putamen
rat
substantia nigra
animal
drug formulation
parkinsonism
pathology
procedures
severity of illness i...
Sprague Dawley rat
treatment outcome
Animals
Drug Compounding
Female
Glial Cell Line-Deriv...
Neuroprotective Agent...
Parkinsonian Disorder...
Rats
Rats, Sprague-Dawley
Severity of Illness I...
Treatment Outcome
Vascular Endothelial ...